The rise of GLP-1 medications like Ozempic is fundamentally reshaping the food industry, with nearly 7% of the U.S. population expected to be on weight loss drugs by 2035. While Walmart's CEO confirmed that customers on these medications are purchasing significantly less food, forward-thinking companies are identifying three key innovation opportunities: developing foods that naturally trigger GLP-1 responses (like beta-glucan and fermentable fibers found in oats, rye, and barley), creating nutritional products to complement GLP-1 therapy, and designing step-down programs for sustainable eating habits when patients discontinue medication. Rather than viewing this $35 billion pharmaceutical trend as purely competitive, the smartest food companies are evolving into healthcare partners, leveraging science-backed nutrition to address the root causes of obesity and diabetes while creating new premium product lines and partnerships with healthcare providers.